May 1, 2024 — Pepper Bio will Gain Exclusive Rights for the Clinical Development, Regulatory Submissions, and Commercialization of Lerociclib in the US, Europe, Japan, and All Other Global Markets Excluding Asia-Pacific.
April 5-10, San Diego Pepper Bio is on a mission to decipher the root causes of diseases and identify effective treatments—thereby illuminating the fastest, safest path to drug discovery. COMPASS, our ML-driven platform, is built on the world's first and largest proprietary transomics database, integrating genomic, transcriptomic, proteomic, and phosphoproteomic data. Our approach offers a comprehensive understanding of biological systems based not just on expression but also on the activity…
Tell us a bit about your background. First, I have to start by saying how appreciative I am because I’ve always had exceptional people supporting me and advising me in my career path. I would say that what I am doing now is an amalgam of all the pieces of the mosaic of my life journey which has been dedicated to improving the healthcare system and advancing the development of…
Pepper Bio landed $6.5 million in seed funding led by NFX. The startup wants to improve the drug-discovery process for pharma companies using AI. Pepper Bio is also developing treatments itself and expects to begin clinical trials next year. Drug discovery is expensive and time-consuming for pharmaceutical and biotech companies. From identifying the right biological targets implicated in a disease, to developing drugs that impact those targets through years-long clinical…
By Jonathan D. Grinstein, PhD My interview with Pepper Bio CEO Jon Hu begins with one of the most frequently repeated phrases I hear when speaking with drug developers: “We are a drug developer trying to tackle untreatable diseases,” Hu says. In Hu’s opinion, however, Pepper Bio’s computational approach that uses “functional” omics data, which they’ve dubbed “transomics,” will set them apart in their quest to combat incurable diseases. So…
NEW YORK — Drug discovery and bioinformatics startup Pepper Bio said on Thursday that it has raised $6.5 million in seed funding. The financing round was led by NFX and included Silverton Partners, Merck Digital Sciences Studio, Mana Ventures, Tensility Ventures, and VSC Ventures. Pepper Bio was founded in 2020 through a Merck-run accelerator program to leverage a multiomics approach — dubbed transomics — to identify new therapeutics, repurpose existing ones, and…